Reeves Mathew J, Broderick Joseph P, Frankel Michael, LaBresh Kenneth A, Schwamm Lee, Moomaw Charles J, Weiss Paul, Katzan Irene, Arora Shalini, Heinrich John P, Hickenbottom Susan, Karp Herbert, Malarcher Ann, Mensah George, Reeves Mathew J
Department of Epidemiology, Michigan State University, East Lansing 48824, USA.
Am J Prev Med. 2006 Dec;31(6 Suppl 2):S202-9. doi: 10.1016/j.amepre.2006.08.007.
This paper summarizes the experiences of the Paul Coverdell National Acute Stroke Registry first four prototype registries in Georgia (GA), Massachusetts (MA), Michigan (MI), and Ohio (OH), and includes information on their sampling design, case ascertainment, and data collection methods, as well as some key findings.
Using a combination of different sampling methods, each prototype obtained a representative statewide sample of hospitals. Acute stroke admissions were identified through prospective (MA, MI) or retrospective (GA, OH) methods. A common set of case definitions and data elements were used by each registry. Weighted site-specific frequencies and 95% confidence intervals were generated for each outcome. A summary estimate, representing a weighted average of the four site-specific estimates, was also calculated.
Of the total 6867 admissions, 1487 (21.6%) were from the GA registry, 1206 (17.6%) from MA, 2566 (37.4%) from MI, and 1608 (23.4%) from the OH prototype. Just less than 60% of admissions were ischemic strokes (site-specific estimates ranged from 52% to 70%), with transient ischemic attack (18.5%) and intracerebral hemorrhage (8.8%) making up most of the remainder. Twenty-one percent of patients admitted were younger than 60 years of age, and 55.3% were women. The proportion of black subjects varied from 7.1% (MI) to 30.6% (GA). Twenty-three percent of admissions arrived at the emergency department within 3 hours of onset. Overall 4.5% of ischemic stroke admissions were treated with recombinant tissue plasminogen activator; site-specific treatment rates were 3.0% (GA), 3.2% (OH), 3.4% (MI), and 8.5% (MA). Only a small minority of treated patients (range, 10.8% [OH] to 19.6% [MI]) received recombinant tissue plasminogen activator within the recommended 1 hour door-to-needle time. A minority of eligible subjects were screened for dysphagia (45.4%), underwent lipid testing (33.6%), or received smoking-cessation counseling (21.4%). In contrast, compliance with antithrombotic treatments at discharge was high (91.5%).
A minority of acute stroke patients are treated according to established guidelines. Quality improvement interventions, targeted primarily at the healthcare systems level, are needed to improve acute stroke care in the United States.
本文总结了保罗·科弗代尔国家急性卒中登记处前四个原型登记处在佐治亚州(GA)、马萨诸塞州(MA)、密歇根州(MI)和俄亥俄州(OH)的经验,包括其抽样设计、病例确定和数据收集方法,以及一些关键发现。
每个原型登记处采用不同抽样方法的组合,获得了具有代表性的全州医院样本。通过前瞻性(MA、MI)或回顾性(GA、OH)方法确定急性卒中入院病例。每个登记处使用一套共同的病例定义和数据元素。为每个结果生成特定地点的加权频率和95%置信区间。还计算了一个汇总估计值,该值代表四个特定地点估计值的加权平均值。
在总共6867例入院病例中,1487例(21.6%)来自佐治亚州登记处,1206例(17.6%)来自马萨诸塞州,2566例(37.4%)来自密歇根州,1608例(23.4%)来自俄亥俄州的原型登记处。缺血性卒中入院病例不到60%(特定地点估计值范围为52%至70%),其余大部分为短暂性脑缺血发作(18.5%)和脑出血(8.8%)。21%的入院患者年龄小于60岁,55.3%为女性。黑人受试者的比例从7.1%(密歇根州)到30.6%(佐治亚州)不等。23%的入院患者在发病后3小时内到达急诊科。总体而言,4.5%的缺血性卒中入院患者接受了重组组织型纤溶酶原激活剂治疗;特定地点的治疗率分别为3.0%(佐治亚州)、3.2%(俄亥俄州)、3.4%(密歇根州)和8.5%(马萨诸塞州)。只有一小部分接受治疗的患者(范围为10.8%[俄亥俄州]至19.6%[密歇根州])在推荐的1小时门到针时间内接受了重组组织型纤溶酶原激活剂治疗。少数符合条件的受试者接受了吞咽困难筛查(45.4%)、血脂检测(33.6%)或戒烟咨询(21.4%)。相比之下,出院时抗血栓治疗的依从性很高(91.5%)。
少数急性卒中患者按照既定指南接受治疗。需要主要针对医疗保健系统层面的质量改进干预措施,以改善美国的急性卒中护理。